Outcomes of ESG and LSG with 12+ Months of Adjuvant Pre- and Postoperative Multidisciplinary Support

Skye Marshall; Prudence Carr; Tim Keighley; Peter Petocz; Graeme Rich; Felicity  Cohen; Asha Soni; Isabella R. Maimone; Flavia Fayet-Moore; Elisabeth Isenring

Abstract

Background: Adults with obesity are electing bariatric procedures including the laparoscopic sleeve gastrectomy (SG) and more recently, the incisionless endoscopic sleeve gastroplasty (ESG). However, their efficacy, safety and patient-centered outcomes require further investigation in the Australian setting. To examine the 6- and 12-month weight loss efficacy, safety, and weight-related quality of life (QoL) of adults with obesity who received the ESG or SG bariatric procedure with 12+ months of adjuvant multidisciplinary pre- and postoperative support.
Methods: Two-arm prospective cohort study followed Australian patients who elected the ESG or SG procedure from baseline to 12-months postoperative. Excess weight loss (EWL) was the primary outcome. Secondary outcomes were body composition via dual energy X-ray absorptiometry, weight-related QoL, lipid, glycemic, and hepatic biochemistry, and adverse events.
Results: 16 (81.2% female; aged 41.4 (SD=10.4)years; BMI=35.5 (SD=5.2)kg/m2) ESG and 45 (84.4% female; aged 40.4 (9.0)years; BMI=40.7 (5.6)kg/m2) SG participants were recruited. At 12-months postprocedure, ESG EWL was 57% (SD: 32%; p<0.01) and SG EWL was 79% (SD: 24; p<0.001). ESG and SG cohorts improved QoL, liver function, and lipid profiles; however, only SG was statistically significant (p<0.001). Both cohorts reduced fat mass (p <0.05). The ESG maintained but SG decreased fat free mass at 6-months (p<0.05). No procedure-related serious adverse events were identified.
Conclusions: In this setting, the ESG and SG were safe and effective weight loss treatments for obese adults alongside multidisciplinary support. The ESG may confer additional benefits in the retention of fat free mass whilst the LSG may lead to greater overall (fat free and fat mass) weight loss. Further well powered studies are required to confirm these findings.
******************************************************************
Video recording of the presentation
Copyright © 2021 Skye Marshall & Felicity Cohen
All rights reserved.
Reproduced with permission
*******************************************************************

Original language	English
Publication status	E-pub ahead of print - Nov 2021
Event	Obesity Week - Virtual , United States Duration: 1 Nov 2021 → 5 Nov 2021 https://obesityweek.org/

Conference

Conference	Obesity Week
Country/Territory	United States
Period	1/11/21 → 5/11/21
Internet address	https://obesityweek.org/

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Poster- The Endoscopic Sleeve Gastroplasty (ESG) & Laparoscopic Sleeve Gastrectomy (LSG) were effective and safe for weight lossAccepted author manuscript, 338 KBLicence: CC BY-NC-ND
Video presentation - The Endoscopic Sleeve Gastroplasty (ESG) & Laparoscopic Sleeve Gastrectomy (LSG) were effective and safe for weight lossOther version, 176 MBLicence: Free to read

https://tos.planion.com/Web.User/AbstractDet?ACCOUNT=TOS&ABSID=25753&CONF=OW2021&ssoOverride=OFF&CKEY=Licence: Free to read

1 Active

Nutrition to optimise surgical outcomes
Marshall, S., Reidlinger, D., O'Neill, H., Isenring, E., Van der Meij, B., Tang, X., Campbell, K. & Kelly, J.
1/01/18 → 30/06/26
Project: Research

1 Meeting Abstract

Outcomes of ESG and LSG with 12+ Months of Adjuvant Pre- and Postoperative Multidisciplinary Support
Marshall, S., Carr, P., Keighley, T., Petocz, P., Rich, G., Cohen, F., Soni, A., Maimone, I. R., Fayet-Moore, F. & Isenring, E., 1 Nov 2023, In: Obesity. 29, p. 134-134 1 p., Poster 218.
Research output: Contribution to journal › Meeting Abstract › Research › peer-review

Cite this

Marshall, S., Carr, P., Keighley, T., Petocz, P., Rich, G., Cohen, F., Soni, A., Maimone, I. R., Fayet-Moore, F., & Isenring, E. (2021). Outcomes of ESG and LSG with 12+ Months of Adjuvant Pre- and Postoperative Multidisciplinary Support. Abstract from Obesity Week, United States. Advance online publication. https://tos.planion.com/Web.User/AbstractDet?ACCOUNT=TOS&ABSID=25753&CONF=OW2021&ssoOverride=OFF&CKEY=

@conference{b05f1549ae8b422a85d4c8013721a587,

title = "Outcomes of ESG and LSG with 12+ Months of Adjuvant Pre- and Postoperative Multidisciplinary Support",

abstract = "Background: Adults with obesity are electing bariatric procedures including the laparoscopic sleeve gastrectomy (SG) and more recently, the incisionless endoscopic sleeve gastroplasty (ESG). However, their efficacy, safety and patient-centered outcomes require further investigation in the Australian setting. To examine the 6- and 12-month weight loss efficacy, safety, and weight-related quality of life (QoL) of adults with obesity who received the ESG or SG bariatric procedure with 12+ months of adjuvant multidisciplinary pre- and postoperative support. Methods: Two-arm prospective cohort study followed Australian patients who elected the ESG or SG procedure from baseline to 12-months postoperative. Excess weight loss (EWL) was the primary outcome. Secondary outcomes were body composition via dual energy X-ray absorptiometry, weight-related QoL, lipid, glycemic, and hepatic biochemistry, and adverse events. Results: 16 (81.2% female; aged 41.4 (SD=10.4)years; BMI=35.5 (SD=5.2)kg/m2) ESG and 45 (84.4% female; aged 40.4 (9.0)years; BMI=40.7 (5.6)kg/m2) SG participants were recruited. At 12-months postprocedure, ESG EWL was 57% (SD: 32%; p<0.01) and SG EWL was 79% (SD: 24; p<0.001). ESG and SG cohorts improved QoL, liver function, and lipid profiles; however, only SG was statistically significant (p<0.001). Both cohorts reduced fat mass (p <0.05). The ESG maintained but SG decreased fat free mass at 6-months (p<0.05). No procedure-related serious adverse events were identified. Conclusions: In this setting, the ESG and SG were safe and effective weight loss treatments for obese adults alongside multidisciplinary support. The ESG may confer additional benefits in the retention of fat free mass whilst the LSG may lead to greater overall (fat free and fat mass) weight loss. Further well powered studies are required to confirm these findings.******************************************************************Video recording of the presentationCopyright {\textcopyright} 2021 Skye Marshall & Felicity CohenAll rights reserved. Reproduced with permission*******************************************************************",

author = "Skye Marshall and Prudence Carr and Tim Keighley and Peter Petocz and Graeme Rich and Felicity Cohen and Asha Soni and Maimone, {Isabella R.} and Flavia Fayet-Moore and Elisabeth Isenring",

year = "2021",

month = nov,

language = "English",

note = "Obesity Week ; Conference date: 01-11-2021 Through 05-11-2021",

url = "https://obesityweek.org/",

}

Marshall, S, Carr, P, Keighley, T, Petocz, P, Rich, G, Cohen, F, Soni, A, Maimone, IR, Fayet-Moore, F & Isenring, E 2021, 'Outcomes of ESG and LSG with 12+ Months of Adjuvant Pre- and Postoperative Multidisciplinary Support', Obesity Week, United States, 1/11/21 - 5/11/21. <https://tos.planion.com/Web.User/AbstractDet?ACCOUNT=TOS&ABSID=25753&CONF=OW2021&ssoOverride=OFF&CKEY=>

TY - CONF

T1 - Outcomes of ESG and LSG with 12+ Months of Adjuvant Pre- and Postoperative Multidisciplinary Support

AU - Marshall, Skye

AU - Carr, Prudence

AU - Keighley, Tim

AU - Petocz, Peter

AU - Rich, Graeme

AU - Cohen, Felicity

AU - Soni, Asha

AU - Maimone, Isabella R.

AU - Fayet-Moore, Flavia

AU - Isenring, Elisabeth

PY - 2021/11

Y1 - 2021/11

N2 - Background: Adults with obesity are electing bariatric procedures including the laparoscopic sleeve gastrectomy (SG) and more recently, the incisionless endoscopic sleeve gastroplasty (ESG). However, their efficacy, safety and patient-centered outcomes require further investigation in the Australian setting. To examine the 6- and 12-month weight loss efficacy, safety, and weight-related quality of life (QoL) of adults with obesity who received the ESG or SG bariatric procedure with 12+ months of adjuvant multidisciplinary pre- and postoperative support. Methods: Two-arm prospective cohort study followed Australian patients who elected the ESG or SG procedure from baseline to 12-months postoperative. Excess weight loss (EWL) was the primary outcome. Secondary outcomes were body composition via dual energy X-ray absorptiometry, weight-related QoL, lipid, glycemic, and hepatic biochemistry, and adverse events. Results: 16 (81.2% female; aged 41.4 (SD=10.4)years; BMI=35.5 (SD=5.2)kg/m2) ESG and 45 (84.4% female; aged 40.4 (9.0)years; BMI=40.7 (5.6)kg/m2) SG participants were recruited. At 12-months postprocedure, ESG EWL was 57% (SD: 32%; p<0.01) and SG EWL was 79% (SD: 24; p<0.001). ESG and SG cohorts improved QoL, liver function, and lipid profiles; however, only SG was statistically significant (p<0.001). Both cohorts reduced fat mass (p <0.05). The ESG maintained but SG decreased fat free mass at 6-months (p<0.05). No procedure-related serious adverse events were identified. Conclusions: In this setting, the ESG and SG were safe and effective weight loss treatments for obese adults alongside multidisciplinary support. The ESG may confer additional benefits in the retention of fat free mass whilst the LSG may lead to greater overall (fat free and fat mass) weight loss. Further well powered studies are required to confirm these findings.******************************************************************Video recording of the presentationCopyright © 2021 Skye Marshall & Felicity CohenAll rights reserved. Reproduced with permission*******************************************************************

AB - Background: Adults with obesity are electing bariatric procedures including the laparoscopic sleeve gastrectomy (SG) and more recently, the incisionless endoscopic sleeve gastroplasty (ESG). However, their efficacy, safety and patient-centered outcomes require further investigation in the Australian setting. To examine the 6- and 12-month weight loss efficacy, safety, and weight-related quality of life (QoL) of adults with obesity who received the ESG or SG bariatric procedure with 12+ months of adjuvant multidisciplinary pre- and postoperative support. Methods: Two-arm prospective cohort study followed Australian patients who elected the ESG or SG procedure from baseline to 12-months postoperative. Excess weight loss (EWL) was the primary outcome. Secondary outcomes were body composition via dual energy X-ray absorptiometry, weight-related QoL, lipid, glycemic, and hepatic biochemistry, and adverse events. Results: 16 (81.2% female; aged 41.4 (SD=10.4)years; BMI=35.5 (SD=5.2)kg/m2) ESG and 45 (84.4% female; aged 40.4 (9.0)years; BMI=40.7 (5.6)kg/m2) SG participants were recruited. At 12-months postprocedure, ESG EWL was 57% (SD: 32%; p<0.01) and SG EWL was 79% (SD: 24; p<0.001). ESG and SG cohorts improved QoL, liver function, and lipid profiles; however, only SG was statistically significant (p<0.001). Both cohorts reduced fat mass (p <0.05). The ESG maintained but SG decreased fat free mass at 6-months (p<0.05). No procedure-related serious adverse events were identified. Conclusions: In this setting, the ESG and SG were safe and effective weight loss treatments for obese adults alongside multidisciplinary support. The ESG may confer additional benefits in the retention of fat free mass whilst the LSG may lead to greater overall (fat free and fat mass) weight loss. Further well powered studies are required to confirm these findings.******************************************************************Video recording of the presentationCopyright © 2021 Skye Marshall & Felicity CohenAll rights reserved. Reproduced with permission*******************************************************************

M3 - Abstract

T2 - Obesity Week

Y2 - 1 November 2021 through 5 November 2021

ER -

Outcomes of ESG and LSG with 12+ Months of Adjuvant Pre- and Postoperative Multidisciplinary Support

Abstract

Conference

UN SDGs

Access to Document

Fingerprint

Related Projects

Nutrition to optimise surgical outcomes

Related Research Outputs

Outcomes of ESG and LSG with 12+ Months of Adjuvant Pre- and Postoperative Multidisciplinary Support

Cite this